Quatre Bornes

Researchers are evaluating the safety and effectiveness of Multi-Gyn FemiTotal, a vaginal gel, for treating and preventing bacterial vaginosis BV and vulvovaginal candidiasis VVC in women. This study includes 40 women with VVC itching symptoms and 49 women with BV confirmed by Amsel criteria. The main goal is to assess how well the gel relieves itching and treats BV and VVC symptoms 21 days after starting treatment. Participants will use the Multi-Gyn FemiTotal vaginal gel for 7 days during the treatment phase. If symptoms are considered cured 21 days after treatment begins, they will enter a prevention phase with follow-up visits up to 4 months after starting treatment to monitor for any recurrence of BV or VVC. This is a single-arm, multicenter clinical investigation. During the study, participants will be assessed by doctors and complete questionnaires to evaluate symptom relief and treatment effectiveness at 21 days. Follow-up evaluations at 4 months will check for the prevention of BV and VVC recurrence. Participants will also be monitored for safety and adherence to the treatment and follow-up schedule. The total study duration for each participant includes treatment and extended follow-up for up to 4 months.

Researchers are evaluating the medical device cream RV4421B-EV0407 for the treatment of various types of eczema, including atopic eczema, contact eczema, and chronic hand eczema. This study involves a diverse group of adults and children, including those with darker skin tones, to assess the safety and efficacy of the cream used alone or alongside topical corticosteroids over a period of 12 weeks with an additional follow-up. Participants will apply the product twice daily, either by itself or with topical corticosteroid therapy, depending on their age group. The study includes three groups infants 3 months to 23 months, children 24 months to 12 years, and teenagers and adults 13 years and older. The product application period lasts up to 87 days. During the study, participants will attend five visits an inclusion visit on day 1, two intermediate visits including one by phone between days 8 and 15 and one on day 29, another visit on day 57, and a final visit on day 85. Researchers will monitor local tolerance to the product, adverse events, and atopic dermatitis severity using various assessments. Quality of life questionnaires and satisfaction surveys will also be completed, with continuous monitoring throughout the study period.